Join the Keppra group to help and get support from people like you.
Keppra News
Two Common Antiseizure Medications Do Not Harm Child Neurodevelopment
TUESDAY, Dec. 3, 2024 -- Fetal exposure to two common antiseizure medications (ASMs) does not seem to negatively impact children's neurological development at age 6 years, according to a study pu...
Newer Epilepsy Meds Safe During Pregnancy, Won't Affect Kids' Neurodevelopment
MONDAY, Dec. 2, 2024 – For decades, it's been known that certain older medications women use to control epilepsy seizures can pose risks to a fetus. However, data now suggests that no such risk ...
FDA Medwatch Alert: FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan)
November 28, 2023 – FDA Warns of Rare But Serious Drug Reaction to the Antiseizure Medicines Levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and Clobazam (Onfi, Sympazan) What safety...
FDA Medwatch Alert: Sagent Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Levetiracetam Injection, USP Due to Lack of Sterility Assurance
CHICAGO, IL – November 19, 2021 - Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of four lots of Levetiracetam Injection, USP, to the user level. The lack of container c...
FDA Medwatch Alert: Lannett Issues Voluntary Nationwide Recall of Levetiracetam Oral Solution, 100mg/mL Due to Microbial Contamination
Lannett Company, Inc. today announced that it is voluntarily recalling two (2) lots of Levetiracetam Oral Solution, 100mg/mL to the consumer level due to contamination with Bacillus subtilis. The...
FDA Medwatch Alert: Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it’s wholly owned subsidiary, Dr Reddy’s Laboratories, Inc is continuing its voluntary nationwide recall of lot ABD8...
UCB Announces FDA Approval for Keppra in Infants and Children from One Month of Age with Partial Onset Seizures
ATLANTA--(BUSINESS WIRE)--Jan 25, 2012 - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in...
FDA Medwatch Alert: Keppra (levetiracetam) Tablets and Oral Solution
FDA and UCB Pharma advised healthcare professionals of the risk of dispensing errors between KEPPRA (levetiracetam), an antiepileptic, and KALETRA (lopinavir/ritonavir), an antiretroviral. Patients...
FDA Medwatch Alert: Antiepileptic Drugs
[UPDATE 05/05/2009] FDA notified healthcare professionals that it approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (e.g., migraine...